Ignite Creation Date:
2024-05-06 @ 8:07 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06258174
Status:
COMPLETED
Last Update Posted:
2024-02-14
First Post:
2024-02-06
Brief Title:
A Study of Two Different Formulations of Pirtobrutinib LOXO-305 In Healthy Participants
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Phase I Open-Label Randomized 2-Way Crossover Study to Compare the PK of Pirtobrutinib LOXO-305 Tablets
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to compare two different formulations mixtures of pirtobrutinib LOXO-305 in healthy participants This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it Information about any side effects that may occur will be collected The study will last up to 65 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J2N-OX-JZNV | OTHER | Eli Lilly and Company | None |